Get the Stockscreener App
8.4287
2.79%
0.2287
Lyra Therapeutics Inc stock is traded at $8.4287, with a volume of 17,711.
It is up +2.79% in the last 24 hours and down -26.64% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$8.20
Open:
$8.19
24h Volume:
17,711
Relative Volume:
0.03
Market Cap:
$11.13M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-5.6568
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
-1.19%
1M Performance:
-26.64%
6M Performance:
-9.51%
1Y Performance:
-43.79%
1-Day Range:
$8.1501
$8.4989
1-Week Range:
$7.85
$8.56
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
8.40 | 13.55M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.70 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.17 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.50 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.92 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.56 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics Inc. Stock Analysis and ForecastBreakthrough profit margins - Autocar Professional
Is Lyra Therapeutics Inc. a good long term investmentConsistent triple returns - Autocar Professional
What drives Lyra Therapeutics Inc. stock priceExponential wealth increase - jammulinksnews.com
Lyra Therapeutics (LYRA) Proposes Sale of 846,744 Shares of Comm - GuruFocus
What analysts say about Lyra Therapeutics Inc. stockExceptional trading performance - jammulinksnews.com
How Lyra Therapeutics Inc. stock performs during market volatilityFree Predictions - Newser
Why Lyra Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - beatles.ru
What makes Lyra Therapeutics Inc. stock price move sharplyFree Stock Market Courses - Newser
Lyra Therapeutics CFO Cavalier sells $6k in shares By Investing.com - Investing.com Canada
Lyra Therapeutics CEO Palasis sells $13944 in stock By Investing.com - Investing.com Nigeria
Lyra Therapeutics CEO Palasis sells $13944 in stock - Investing.com
Lyra Therapeutics (NASDAQ:LYRA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Lyra Therapeutics Secures $4.3M in Direct Offering - TipRanks
Is Lyra Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Lyra Therapeutics regains Nasdaq compliance as stock maintains $1 minimum - Investing.com UK
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise
H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada
Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus
H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
4.61%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):